AF
Organon (2) Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Elyea (relugolix combo) | Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain | Approved |
| Phexxi | Non-hormonal Contraceptive | Approved |
| Orilissa (elagolix) | Endometriosis Pain | Approved |
| Biosimilar Aflibercept | Ophthalmology (nAMD, DME) | Filed |
| Biosimilar Denosumab | Osteoporosis, Bone Metastasis | Phase 3 |
| Biosimilar Ranibizumab | Ophthalmology (nAMD, DME, RVO) | Phase 3 |
| Biosimilar Ustekinumab | Plaque Psoriasis, Psoriatic Arthritis, IBD | Phase 3 |
| Biosimilar Bevacizumab | Oncology | Phase 3 |
Leadership Team at Organon (2)
CC
Carrie Cox
Executive Board Chair
JM
Joseph Morrissey
Interim CEO
JC
Juan Camilo Arjona Ferreira
Head of R&D and Chief Medical Officer
MC
Mike Casia
Interim Head of U.S. Commercial & Government Affairs
JD
Juliana Drinane
Interim Head of Manufacturing and Supply
DK
Daniel Karp
Head of Corporate Development and Chief Strategy Officer
VN
Vittorio Nisita
Head of Enterprise Services & Solutions
RS
Rachel Stahler
Chief Digital and Growth Officer
NV
Nico Van Hoecke
Head of International Commercial
MW
Matthew Walsh
Chief Financial Officer